Recombinant Anti-Notch 2 (Clone B6)
| Applications | Bl, ELISA, IF |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Notch 2 (Clone B9)
| Applications | Bl, ELISA, IF |
| Reactivities | Human, Mouse |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Glucose-dependent insulinotropic Receptor (Clone Gipg013)
| Applications | Bl, ELISA, IF |
| Reactivities | Human, Mouse, Rat, Dog |
| Conjugation | Unconjugated |
| Modifications | This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Discoidin Domain Receptor 1 (Clone 3E3)
| Applications | Bl, ELISA, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TrkA (Clone MNAC13)
| Applications | Bl, ELISA, IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD62L (Clone DREG-56)
| Applications | Bl, FC, IP, WB |
| Reactivities | Bovine, Chimpanzee, Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD44 (Clone Hermes-1)
| Applications | Bl, ELISA, FC, IF, IHC, IP, Neutralize, WB |
| Reactivities | Bovine, Goat, Human, Mouse, Primate, Rabbit, Rat, Sheep |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD44 (Clone Hermes -3)
| Applications | Bl, ELISA, FC, ICC, IF, IHC, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD22 (Clone hL22 (Epratuzumab))
| Applications | Bl, FC, IP |
| Reactivities | Human, Monkey |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD47 (Clone mIAP430)
| Applications | Bl, IF |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-DARC (Clone 2C3)
| Applications | Bl, ELISA, FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD131 (Clone BION-1)
| Applications | Bl, IHC, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-Protein C (Clone HPC-4)
| Applications | Bl, ELISA |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-IL-9R (Clone AH9R2)
| Applications | Bl, IP |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-TLR2 (Clone TL2.1)
| Applications | Bl, FC, IF, IP, WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD36 (Clone 185-1G2 (B467))
| Applications | Bl, FC, IF, IHC, IP |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-CD106 (Clone B-K9 (C106-K9))
| Applications | Bl, FC |
| Reactivities | Human |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. |
Recombinant Anti-C5aR (Clone S5/1)
| Applications | Bl, ELISA, FC, IP, WB |
| Reactivities | Ferret, Human, Rabbit, Cow |
| Conjugation | Unconjugated |
| Modifications | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. |
Germany
Japan
United Kingdom
China
